Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

Gynecologic Oncology

Volumn 133, Issue 1, 2014, Pages 16-22

  Au Yeung, George ^a   Webb, Penelope M ^c   Defazio, Anna ^d   Fereday, Sian ^a   Bressel, Mathias ^a   Mileshkin, Linda ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemotherapy dosing; Dose intensity; Obesity; Ovarian cancer; Overall survival; Progression free survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CREATININE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; YOUNG ADULT;

CHEMOTHERAPY DOSING; DOSE INTENSITY; OBESITY; OVARIAN CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CARBOPLATIN; CARCINOMA; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVARIAN NEOPLASMS; OVERWEIGHT; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84897082114     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.030     Document Type: Article

References (31)

1. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 11 2010 803 808
2. S.L. Cooke, and J.D. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol 2011;12(12):1169-74
3. S.V. Barrett, J. Paul, A. Hay, P.A. Vasey, S.B. Kaye, and R.M. Glasspool Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial, Ann Oncol 19 5 2008 898 902
4. J.C. Pavelka, R.S. Brown, B.Y. Karlan, I. Cass, R.S. Leuchter, and L.D. Lagasse et al. Effect of obesity on survival in epithelial ovarian cancer Cancer 107 7 2006 1520 1524
5. K.S. Matthews, J.M. Straughn Jr., M.K. Kemper, K.E. Hoskins, W. Wang, and R.P. Rocconi The effect of obesity on survival in patients with ovarian cancer Gynecol Oncol 112 2 2009 389 393
6. D.H. Suh, H.S. Kim, H.H. Chung, J.W. Kim, N.H. Park, and Y.S. Song et al. Body mass index and survival in patients with epithelial ovarian cancer J Obstet Gynaecol Res 38 1 2012 70 76
7. F.J. Backes, C.I. Nagel, E. Bussewitz, J. Donner, E. Hade, and R. Salani The impact of body weight on ovarian cancer outcomes Int J Gynecol Cancer 21 9 2011 1601 1605
8. M. Protani, C.I Nagel, A. DeFazio, L. Mileshkin, and P.M. Webb Obesity and survival in women with ovarian cancer: results from the Australian Ovarian Cancer Study, a systematic review and meta-analysis Australia New Zealand Gynaecological Oncology Group Annual Scientific Meeting; 2013 21 Mar.; Gold Coast, Queensland, Australia 2013
9. M.M. Protani, C.M. Nagle, and P.M. Webb Obesity and ovarian cancer survival: a systematic review and meta-analysis Cancer Prev Res (Phila) 5 7 2012 901 910
10. G.H. Lyman, D.C. Dale, and J. Crawford Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 24 2003 4524 4531
11. J.J. Griggs, M.E. Sorbero, and G.H. Lyman Undertreatment of obese women receiving breast cancer chemotherapy Arch Intern Med 165 11 2005 1267 1273
12. K.M. Field, S. Kosmider, M. Jefford, M. Michael, R. Jennens, and M. Green et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey J Oncol Pract 4 3 2008 108 113
13. G. Bonadonna, P. Valagussa, A. Moliterni, M. Zambetti, and C. Brambilla Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 14 1995 901 906
14. G.L. Rosner, J.B. Hargis, D.R. Hollis, D.R. Budman, R.B. Weiss, and I.C. Henderson et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541 J Clin Oncol 14 11 1996 3000 3008
15. M. Colleoni, S. Li, R.D. Gelber, K.N. Price, A.S. Coates, and M. Castiglione-Gertsch et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index Lancet 366 9491 2005 1108 1110
16. G.H. Lyman Impact of chemotherapy dose intensity on cancer patient outcomes J Natl Compr Cancer Netw 7 1 2009 99 108
17. S.J. Jordan, A.C. Green, D.C. Whiteman, S.P. Moore, C.J. Bain, and D.M. Gertig et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis Int J Cancer 122 7 2008 1598 1603
18. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 11 1989 1748 1756
19. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1 1976 31 41
20. D. Du Bois, and E.F. Du Bois A formula to estimate the approximate surface area if height and weight be known. 1916 Nutrition 5 5 1989 303 311
21. J.J. Griggs, P.B. Mangu, H. Anderson, E.P. Balaban, J.J. Dignam, and W.M. Hryniuk et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 30 13 2012 1553 1561
22. I.M. Collins, R. Roberts-Thomson, D. Faulkner, D. Rischin, M. Friedlander, and L. Mileshkin Carboplatin dosing in ovarian cancer: problems and pitfalls Int J Gynecol Cancer 21 7 2011 1213 1218
23. W.K. Nelson, R.N. Formica Jr., D.L. Cooper, P.E. Schwartz, and T.J. Rutherford An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers J Oncol Pharm Pract 18 3 2012 323 332
24. E. Lepage, C. Gisselbrecht, C. Haioun, C. Sebban, H. Tilly, and A. Bosly et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte) Ann Oncol 4 8 1993 651 656
25. J.M. Fauci, J.M. Whitworth, K.E. Schneider, A. Subramaniam, B. Zhang, and P.J. Frederick et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer Gynecol Oncol 122 3 2011 532 535
26. C.I. Nagel, F.J. Backes, E.M. Hade, D.E. Cohn, E.L. Eisenhauer, and D.M. O'Malley et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer Gynecol Oncol 124 2 2012 221 224
27. C.K. Lee, H. Gurney, C. Brown, R. Sorio, N. Donadello, and G. Tulunay et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer Br J Cancer 105 3 2011 360 365
28. K.C. Hourdequin, W.L. Schpero, D.R. McKenna, and B.L. Piazik Larson RJ Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis, Ann Oncol 24 12 2013 2952 2962
29. F. Abu Saadeh, L. Norris, S. O'Toole, and N. Gleeson Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival Eur J Obstet Gynecol Reprod Biol 2013;170(1):214-8
30. D. Califano, S. Pignata, N.S. Losito, A. Ottaiano, S. Greggi, and V. De Simone et al. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer J Cell Physiol 2014;229(1):53-9
31. E.S. Diaz, B.Y. Karlan, and A.J. Li Obesity-associated adipokines correlate with survival in epithelial ovarian cancer Gynecol Oncol 129 2 2013 353 357